Using I-124 PET/CT imaging for thyroid cancer evaluation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the clinical utility of I-124 PET/CT imaging and dosimetry in patients with thyroid cancer. It focuses on evaluating the extent of remnant tissue after total thyroidectomy, distinguishing between nodal metastases and remnant tissue, and assessing responses to RAI ablation. Additionally, it will evaluate suspected recurrent or metastatic disease and the RAI avidity of recurrent thyroid cancer in patients undergoing treatment with thyroid kinase inhibitors. The study includes both newly diagnosed patients and those with known or suspected disease.

Why it matters

Who can join: the full rules

Inclusion Criteria

* Post-total thyroidectomy patients with diagnosis of thyroid cancer, any histology, subtype, any ATA risk category, for evaluation for residual disease, cervical or remote metastatic disease
* Patients with known or suspected recurrent/metastatic thyroid cancer, identified by ultrasound (US), CT/MR/FDG-PET\|CT or elevated thyroglobulin (Tg).
* Pretreatment and post-treatment evaluation of patients with thyroid cancer deemed RAI-indifferent/refractory who are considered for TKI
* Age ≥ 18
* Ability and willingness to give a written consent
* Life expectancy \> 3 months
* ECOG performance status ≤ 2

Exclusion Criteria

* Cancers metastatic to thyroid
* Age \< 18
* Inability or unwillingness to give a written consent
* Life expectancy \< 3 months
* ECOG performance status ≥ 3
* Pregnant and nursing women.

Where it's running

• Miami Cancer Research Center
  North Miami, Florida, United States Recruiting

Study contacts

• Principal investigator: Seza Gulec, MD — Ceo, Mcrc
• Study coordinator: Seza Gulec, MD
• Email: sezagulec@gmail.com
• Phone: 786-693-0821

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MRG003 added to ongoing treatment after progression in EGFR-positive advanced thyroid cancer

  In this study, researchers test whether adding MRG003 to a patient’s current thyroid cancer treatment can shrink tumors for those whose cancer initially responded but later progressed.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT07874321

• Selective coverage radiotherapy vs. full coverage radiotherapy for poorly differentiated and anaplastic thyroid cancer

  This trial tests whether covering only the tumor-affected area with radiation is as effective as full-area coverage radiotherapy for poorly differentiated and anaplastic thyroid cancer, while aiming to reduce side effects and improve quality of life.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07777536

• Trop-2 Targeted PET/CT for Recurrent and Metastatic Thyroid Cancer

  This study tests whether a Trop-2 targeted PET/CT scan can better detect recurrent or metastatic thyroid cancer in adults than another PET/CT scan (FAPI).

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07753499

• WeChat-supported neck exercises after thyroidectomy

  A telehealth program using a WeChat mini program tests if guided neck exercises after thyroid surgery help early recovery and quality of life.

  Recruiting Shanghai 6th People's Hospital · Shanghai, Shanghai Municipality · NCT07707401

• Pralsetinib Drug Interaction Study in RET Fusion/MUTATION Positive Solid Tumors

  This trial tests whether pralsetinib changes how the body processes certain medicines in adults with RET fusion- or mutation-positive advanced solid tumors.

  Recruiting at 2 sites Phase 4 Rigel Pharmaceuticals · Logroño, La Rioja and 1 other locations · NCT07704658

• AI chatbot to guide thyroid cancer patients through perioperative education

  A new AI chatbot is being tested to see if it helps thyroid cancer patients better prepare for discharge, recover well, and stay engaged in their care compared with traditional education.

  Recruiting Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07634978

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.